Autoantibodies Activating Human β 1 -Adrenergic Receptors Are Associated With Reduced Cardiac Function in Chronic Heart Failure
Key result
Activating autoantibodies against human beta-adrenergic receptors were present in 26% of patients with dilated cardiomyopathy versus 1% in healthy subjects, and associated with poorer cardiac function.
Why the study?
Are autoantibodies activating human beta-1-adrenergic receptors associated with reduced cardiac function in patients with chronic heart failure?
Population
104 patients with dilated or ischemic cardiomyopathy and 108 healthy subjects
Comparison
Screening for IgG autoantibodies against human… vs Healthy subjects
Design
Case-control
Authors
Discussion
Loading...
Member takes
Implication
Autoantibodies may mark higher-risk dilated cardiomyopathy; leaves open immunomodulatory strategies in heart failure.
Study Design
Type
Case-Control (n=212)
Structured PICO
Are autoantibodies activating human beta-1-adrenergic receptors associated with reduced cardiac function in patients with chronic heart failure?
P
Population
104 patients with dilated or ischemic cardiomyopathy (NYHA functional classes II to IV) and 108 healthy subjects
I
Intervention
Screening for IgG autoantibodies against human beta-1-adrenergic receptors and in vitro functional analysis
C
Comparator
Healthy subjects
O
Outcome
Prevalence of activating autoantibodies against human beta-adrenergic receptors and their association with left ventricular functionsurrogate
Main Result
Absolute Event Rate: 26% vs 1%
Activating autoantibodies against human beta-1-adrenergic receptors are present in a significant subset of patients with dilated cardiomyopathy and are associated with reduced left ventricular function, providing a potential mechanistic rationale for the efficacy of beta-blockers in heart failure.
Cite This Study
Jahns et al. (1999) conducted a case-control in Dilated or ischemic cardiomyopathy (n=212). Autoantibodies against human beta-1-adrenergic receptors vs. Healthy subjects was evaluated on Prevalence of activating autoantibodies against native human beta-adrenergic receptors. Activating autoantibodies against human beta-adrenergic receptors were present in 26% of patients with dilated cardiomyopathy versus 1% in healthy subjects, and associated with poorer cardiac function.